A pioneering collaboration between Omnigene Medical Technologies Ltd and the University of Malta is developing a liquid biopsy platform that could transform how cancer is monitored. Called M3Profiler, the technology analyses tumour-derived exosomes – tiny vesicles released into the bloodstream by cancer cells – to generate detailed molecular profiles from just a small blood sample.